Payments from drug firms to health professionals widespread, review finds
It recommends that the Health Service Executive should highlight that it does not support pharmaceutical industry payments to HSE healthcare professionals, accepting that such payments may influence behaviour in a negative way in terms of prescribing medicines.
Data analysis for 2023 for the study shows that drug companies in Ireland made 4,509 payments to healthcare professionals and healthcare organisations, amounting to over €14.4m that year.
The highest individual payment during the year by a drug company was €50,462 to a medical practitioner.
There were 3,508 payments to healthcare professionals, amounting to €5.5m and 64 payments that exceeded €8,000.
The review was conducted by Professor Michael Barry, Clinical Director of the National Centre for Pharmacoeconomics, which conducts assessments on the cost effectiveness of medicines for the HSE to consider, when making decisions on whether medicines should be made available for the public system.
Prof Barry has advised the HSE that it should demand a 100% disclosure rate for all healthcare professionals and healthcare organisations in receipt of payments from the pharmaceutical industry.
In his review of the 2023 payments, Prof Barry says that drug companies fund many healthcare settings, like hospitals and universities, where education and professional development take place. The industry also funds some medical societies.
Prof Barry said the concern is not only are some societies involved in the education, research and development of prescribers, but some may also be involved in generating treatment guidelines.
The payments by companies are publicly disclosed in accordance with the Irish Pharmaceutical Healthcare Association (IPHA) code of practice since 2016.
The details on the public website www.transferofvalue.ie come from up to 50 companies, including non-IPHA members.
The payments, officially called Transfer of Value, are made for research and development, donations and sponsorship (including medical education), consultancy fees, registration fees for health staff and travel costs to attend events.
The company that made the greatest number of payments to healthcare professionals was Novartis, with 374 such payments.
Abbvie paid the most to healthcare professionals, amounting to €880,952.
Prof Barry said that many would consider that the pharmaceutical industry should not have any role in the education of healthcare professionals and prescribers.
He said that the medical literature has highlighted that doctors with ties to industry may be more inclined than their colleagues to prescribe a brand name drug, despite the availability of a cheaper generic version.
Pharmaceutical industry 'committed to integrity and transparency'
The Irish Pharmaceutical Healthcare Association (IPHA) said that under the latest data for 2024, a record level of 98% of healthcare professionals had provided named transparency on the payments received.
It said that since 2016, companies have disclosed the financial payments, whether direct, or indirect, in cash or in kind, made to healthcare professionals and healthcare organisations.
It also said that the latest data for 2024, just published, shows that payments to healthcare professionals came to €5.6m, a 4% decrease on the 2023 figure.
It added that €178,169 was paid to 74 unnamed healthcare professionals last year, according to the data.
The IPHA said the total amount paid to healthcare organisations last year was also down 3%, at over €8.6m, compared to the previous year.
All healthcare organisations in receipt of the payments were disclosed individually last year, which the association said meant 100% transparency.
The IPHA said that while its members are required to disclose the payments, currently, of the 51 companies who publish their data through the platform, 11 are non-IPHA members and 40 are IPHA members.
The association said it is committed to integrity and transparency in all these interactions and the aim is to reach 100% named disclosure for healthcare professionals and it will support member companies in using legitimate interest, as a legal basis for making these disclosures under data protection law.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Independent
5 hours ago
- Irish Independent
'We said thank you to Joe from the ladies of Ireland' – Louth breastcare provider on Joe Duffy's last show
Louth businesswoman Alison McCabe, who runs the Breastcare by Alison service for women who have had mastectomies while undergoing treatment for breast cancer, was among the guests at Joe Duffy's final Liveline Show on Friday June 2 Alison along with Caroline Davis from Caroline's Breastcare in Carlow were invited to the RTE studios for Joe's last show as they had featured on Liveline in May 2024 when Joe gave them a platform to speak against HSE proposals to cut funding allowances for women who had breast cancer.
Irish Independent
5 hours ago
- Irish Independent
Meath has lowest number of doctors in Ireland amid growing GP crisis, says Aontú leader
The Meath West TD was responding to a recent report highlighting the nationwide shortage of general practitioners (GPs) and said the government is failing to ensure doctor numbers keep pace with population growth. Mr Tóibín said: 'Meath has the lowest number of doctors per capita in the country. As chair of the Save Navan Hospital Campaign I am acutely aware that many of the people using the Emergency Department every day are there because they can't get a doctor.' 'I have had pregnant mothers contact me because they can't get a GP. It can take up to 10 days to get a doctor's appointment even if you have a GP. One man I know contacted 12 GP surgeries in one day and could not get an appointment.' He added that many long-time Meath residents still rely on their original GPs in Dublin because they have been unable to register with a local practice. Mr Tóibín also criticised the government's approach to medical education and the increasing trend of doctor emigration. He cited figures showing that in 2022, 442 Irish doctors were granted temporary work visas for Australia—more than half the number who graduated the previous year. 'We are not training enough GPs for the population increase and many GPs are emigrating because pay, terms and conditions are better abroad,' he said. 'A survey released in the Irish Journal of Medical Science in 2023 outlined that in 2021, of the 2016 cohort of doctors awarded Certificates of Satisfactory Completion of Specialist Training (CSCST), 68pc are employed in Ireland and 32pc are abroad or unknown – a third are not working in the Irish health service.' Mr Tóibín also raised concerns about the rising proportion of non-EU students in Irish medical schools. He referenced data obtained through a Dáil question which revealed that over half of undergraduate medical students now come from outside the EU—many of whom are expected to return to their home countries after qualifying. He added: 'The Universities are dependent on these students for income denied to them by the government. The problem with this is that many of those students will want to practice in their home countries. They will be lost to Ireland. Talk about extra places in Universities is meaningless unless these places lead to extra doctors for Ireland.' Recently, Aontú launched 'Operation Shamrock,' a campaign aimed at attracting Irish-trained medical professionals back to the country. Mr Tóibín said its success will depend on improving working conditions within the HSE and ensuring sustainable patient-to-doctor ratios. 'We need to prioritise places in Irish Medical Schools for students who will work in the Irish health service.' Funded by the Local Democracy Reporting Scheme.
RTÉ News
10 hours ago
- RTÉ News
Payments from drug firms to health professionals widespread, review finds
A new review has found that the practice of drug company payments to healthcare professionals and health organisations in Ireland is widespread. It recommends that the Health Service Executive should highlight that it does not support pharmaceutical industry payments to HSE healthcare professionals, accepting that such payments may influence behaviour in a negative way in terms of prescribing medicines. Data analysis for 2023 for the study shows that drug companies in Ireland made 4,509 payments to healthcare professionals and healthcare organisations, amounting to over €14.4m that year. The highest individual payment during the year by a drug company was €50,462 to a medical practitioner. There were 3,508 payments to healthcare professionals, amounting to €5.5m and 64 payments that exceeded €8,000. The review was conducted by Professor Michael Barry, Clinical Director of the National Centre for Pharmacoeconomics, which conducts assessments on the cost effectiveness of medicines for the HSE to consider, when making decisions on whether medicines should be made available for the public system. Prof Barry has advised the HSE that it should demand a 100% disclosure rate for all healthcare professionals and healthcare organisations in receipt of payments from the pharmaceutical industry. In his review of the 2023 payments, Prof Barry says that drug companies fund many healthcare settings, like hospitals and universities, where education and professional development take place. The industry also funds some medical societies. Prof Barry said the concern is not only are some societies involved in the education, research and development of prescribers, but some may also be involved in generating treatment guidelines. The payments by companies are publicly disclosed in accordance with the Irish Pharmaceutical Healthcare Association (IPHA) code of practice since 2016. The details on the public website come from up to 50 companies, including non-IPHA members. The payments, officially called Transfer of Value, are made for research and development, donations and sponsorship (including medical education), consultancy fees, registration fees for health staff and travel costs to attend events. The company that made the greatest number of payments to healthcare professionals was Novartis, with 374 such payments. Abbvie paid the most to healthcare professionals, amounting to €880,952. Prof Barry said that many would consider that the pharmaceutical industry should not have any role in the education of healthcare professionals and prescribers. He said that the medical literature has highlighted that doctors with ties to industry may be more inclined than their colleagues to prescribe a brand name drug, despite the availability of a cheaper generic version. Pharmaceutical industry 'committed to integrity and transparency' The Irish Pharmaceutical Healthcare Association (IPHA) said that under the latest data for 2024, a record level of 98% of healthcare professionals had provided named transparency on the payments received. It said that since 2016, companies have disclosed the financial payments, whether direct, or indirect, in cash or in kind, made to healthcare professionals and healthcare organisations. It also said that the latest data for 2024, just published, shows that payments to healthcare professionals came to €5.6m, a 4% decrease on the 2023 figure. It added that €178,169 was paid to 74 unnamed healthcare professionals last year, according to the data. The IPHA said the total amount paid to healthcare organisations last year was also down 3%, at over €8.6m, compared to the previous year. All healthcare organisations in receipt of the payments were disclosed individually last year, which the association said meant 100% transparency. The IPHA said that while its members are required to disclose the payments, currently, of the 51 companies who publish their data through the platform, 11 are non-IPHA members and 40 are IPHA members. The association said it is committed to integrity and transparency in all these interactions and the aim is to reach 100% named disclosure for healthcare professionals and it will support member companies in using legitimate interest, as a legal basis for making these disclosures under data protection law.
